23:22 , Nov 10, 2016 |  BC Week In Review  |  Company News

Bendeka sales and marketing update

Teva and Eagle said CMS issued a J-code, effective Jan. 1, for Bendeka bendamustine. The drug is marketed in the U.S. to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin lymphoma (NHL) that...
00:32 , Jun 11, 2016 |  BC Extra  |  Company News

Eagle soars after bendamustine patent ruling

A judge in the U.S. District Court for the District of Delaware upheld most claims of a patent from the Cephalon Inc. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) covering cancer drug Treanda bendamustine. Eagle...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Company News

Eagle Pharmaceuticals, Teva sales and marketing update

Teva launched Bendeka bendamustine in the U.S. to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

Bendeka bendamustine regulatory update

FDA approved an NDA from Eagle for Bendeka bendamustine to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Company News

Eagle Pharmaceuticals, Teva deal

Eagle received a $15 million milestone payment from Teva under a 2015 deal granting Teva exclusive, U.S. rights to commercialize Bendeka bendamustine to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma...
02:11 , Dec 9, 2015 |  BC Extra  |  Company News

FDA approves Bendeka for CLL, NHL

FDA approved Bendeka bendamustine RTD ( EP-3102) from Teva Pharmaceutical Industries Inc. (NYSE:TEVA) and Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) to treat chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma that has progressed during or within...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Event planner

For investors who are not inclined to sit it out until the volatility abates, the fourth quarter is bursting with late-stage catalysts. There are no fewer than 17 PDUFA dates on the calendar before year...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Bendamustine RTD regulatory update

FDA accepted for review an NDA for EP-3102 to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a...
01:49 , Mar 18, 2015 |  BC Extra  |  Financial News

Funding roundup: Valeant, Eagle

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) raised $1.5 billion in follow-on offerings on Tuesday. Valeant raised $1.45 billion through the sale of 7.3 million shares in the U.S. at $199....